home - Kinnear Pharmaceuticals

Harnessing the Power of the Innate Immune System: Introducing Ceragenins, a Versatile Immunomodulatory drug platform for Eradicating Pseudomonas Aeruginosa and a Range of Bacterial and Fungal Infections in Cystic Fibrosis and other diseases.

In 2023 FDA granted our request to designate CSA-131 as a QIDP for the prevention / treatment of CF infections caused by Candida auris, Aspergillus, Pseudomonas, and Klebsiella pneumoniae.

Overview

At Kinnear Pharmaceuticals, we’re pioneering the future of anti-infective and anti-inflammatory therapies. As a dynamic, preclinical stage company, our focus is on developing innovative Ceragenin-based treatments to address diseases that currently lack effective solutions. Our mission is deeply rooted in discovering, developing, and bringing to market revolutionary product candidates.

Kinnear Pharmaceuticals is a subsidiary of N8 Biosciences (www.n8medical.com), a holding company dedicated to the broad application of Ceragenins. N8 Biosciences focus includes the commercialization of CeraShield technology, a specialized coating for medical devices aimed at preventing hospital-acquired infections (HAIs).

Science

Ceragenins : A Synthesis of Nature and Innovation

Inspired by nature

Ceragenins are synthetic non-peptide small molecules modeled after host defense peptides, vital components of our innate immune system. Ceragenins mimic and enhances LL-37, reduce and inhibit IL-6, without creating antimicrobial resistance

Unique capabilities

They exhibit an array of pharmacological activities, including antimicrobial and anti-inflammatory effects, similar to their natural counterparts.

Proven and pat

Backed by extensive research (Since 2019 there have been 350 peer-reviewed journal articles about the Ceragenins technology), patents, and significant investments, Ceragenins are a breakthrough in medical science. Structure: Featuring a sterol backbone adorned with amino acids and other groups, they have a positive charge that targets the negatively charged cell membranes of many pathogens.

Pipeline

Our Key Focus: Developing a Versatile Antibiotic to Prevent and Treat Cystic Fibrosis, Multiple Myeloma, and Dengue.

News

FDA grants QIDP Designation For Kinnear’s CSA-131 drug for Life-threatening Pseudomonas Bacterial Infections in CF

•

August 25, 2023

FDA QiDP designation is a significant milestone PARK CITY, UTAH, UNITED STATES, July 31, 2023/EINPresswire.com/ — Kinnear Pharmaceuticals, LLC, a subsidiary of

Published Research Shows CSA-131’s Potent Efficacy against Global Health Threat

•

April 5, 2018

New Publication regarding Ceragenin CSA-131’s Potent Efficacy against fungal pathogen Candida auris, a New Serious Global Health Threat

Colistin Resistance on the Rise

•

July 12, 2016

Colistin is the last agent used to combat bacteria that are resistant to the strongest antibiotics. Colistin has remained the best tool

Lets Get in Touch!

Follow now